Drug Profile
SB 205614
Alternative Names: Calcitonin intranasal - GlaxoSmithKlineLatest Information Update: 22 Mar 2000
Price :
$50
*
At a glance
- Originator Unknown
- Developer GlaxoSmithKline
- Class Calcium regulators; Osteoporosis therapies
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 22 Mar 2000 No-Development-Reported for Postmenopausal osteoporosis in USA (Intranasal)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Postmenopausal osteoporosis in USA (Intranasal)